17^th May 2019 - The Global Acute Heart Failure (AHF) Therapeutics Market is anticipated to rise at a staggering CAGR during the forecast period. Acute heart failure syndromes comprise a broad range of clinical representations to patient conditions in some aspect of cardiac function. It represents a wider array of pathologies, treatment and a chronic heart condition.

Acute heart failure (AHF) is a common heart condition resulting out of acute and chronic heart conditions leading to cardiac function. However, while the patient opts for treatment, haemodynamic parameters, ventricular function, end-organ perfusion and respiratory function can vary. In such conditions, tailored treatment proves to be the best choice for patients with acute heart failure conditions.

Request a Sample Copy of this Report @ https://www.millioninsights.com/industry-reports/acute-heart-failure-ahf-therapeutics-market/request-sample

By disorder type, acute heart failure (AHF) therapeutics market is segmented as left-sided heart failure, right-sided heart failure, diastolic failure and systolic failure. Drug category segment comprises angiotensin II receptor blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin-receptor neprilys in inhibitors and beta-blockers. Distribution channel segment for acute heart failure (AHF) therapeutics market comprises retail pharmacies, online pharmacies and hospital pharmacies. Hospital pharmacies account for a significant market share due to rise in demand

Geographical segmentation for market is North America, Latin America, Europe, Asia-Pacific, Middle East and Africa. North America is likely to gain a significant CAGR during the forecast period due to increase in prevalence of acute heart disease failure cases and increase in prevalence of obesity. Sedentary lifestyle and high risk of heart disease triggers the market demand for heart failure therapeutics.

Asia-Pacific regions are more likely to gain a significant share in international market due to availability of medical infrastructure and rise in number of heart patients are contributing to the regional market growth. European market follows the trend. The key players profiled in the acute heart failure (AHF) therapeutics market report are Bristol-Myers Squibb Company, Amgen Inc, Cytokinetics Inc, Merck & Company, Pfizer Inc, Ono Pharmaceutical Co Ltd, Novartis AG and Cardiorentis AG.

Access Detailed Report with TOC @ https://www.millioninsights.com/industry-reports/acute-heart-failure-ahf-therapeutics-market

Acute heart failure (AHF) is a progressive condition, in which, the heart muscle is unable to pump enough blood through the heart to meet body’ optimal blood and oxygen level. Congestive heart failure is type of heart failure which requires timely medical attention. Moreover, distinguish between acute and chronic heart failure is important from a clinical standpoint, on which further medication depends. For this, N terminal proB-type natriuretic peptide levels are used for distinguishing acute versus chronic left ventricular dysfunction. An elevated levels of natriuretic peptide were present in patients with acute heart failure compared to those with chronic heart failure patient.

Heart failure symptoms vary widely from person to person, depending on types of heart failure patient. The main symptoms of heart failure are caused due to fluid accumulation or congestion and poor blood flow to the body. Symptoms caused by fluid accumulation or congestion includes shortness of breath, weight gain, coughing, swollen ankles, legs or abdomen, while dizziness, rapid heart rate, and fatigue are symptoms associated with reduced blood flow to parts of the body.

Get FREE In-Depth Sample Copy of Research @ https://www.coherentmarketinsights.com/insight/request-sample/1910

Acute Heart Failure (AHF) Therapeutics Market – Drivers

The global acute heart failure therapeutics market is expected to witness significant growth due to approval of new drugs. For instance, in July 2015, Novartis received U.S. Food and Drug Administration (FDA) approval for their Entresto(TM) (sacubitril/valsartan) tablets on the treatment of heart failure with reduced ejection fraction. Entresto is indicated to reduce the risk of cardiovascular death and heart failure hospitalization.

Furthermore, robust pipeline of drugs over the forecast period (2018-2026), is another factor driving growth of acute heart failure therapeutics market. For instance, in March 2017, Cardioxyl Pharmaceuticals’ CXL-1427: a novel nitroxyl (HNO) donor (prodrug), which now operates under the Bristol-Myers Squibb Company (after Cardioxyl Pharmaceuticals’ acquisition by Bristol-Myers Squibb in December 2015); is present in Phase 2 clinical development phase. CXL-1427 is indicated to use as an intravenous treatment for acute decompensated heart failure (ADHF). Successful completion and further launch of Bristol-Myers Squibb’s innovative drug in future, will help to boost the acute heart failure (AHF) therapeutics market growth during the forecast period.

Acute Heart Failure (AHF) Therapeutics Market – Regional Analysis

Geographically, the market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America is expected to hold dominant position in global acute heart failure (AHF) therapeutics market, due to high prevalence of acute heart failure cases, in this region. For instance, according to Centers for Disease Control and Prevention (CDC), June 2016, around 5.7 million adults in the U.S. suffered from heart failure, in 2016. Moreover, about half of the people who develop heart failure die within 5 years of diagnosis.

Acute Heart Failure (AHF) Therapeutics Market – Competitive Landscape

Some of the key players in this market are Novartis AG, Cardiorentis AG, Bristol-Myers Squibb Company, Amgen Inc., Bayer AG, Cytokinetics, Inc., Merck & Company, Inc., Ono Pharmaceutical Co., Ltd., and Pfizer Inc., among others. Key players in the marker are engaged in development of new drugs for acute heart failure (AHF). These players are incorporating collaboration strategies to remain competitive in the market.

Acute Heart Failure (AHF) Therapeutics Market – Taxonomy

By Disorder Type:

Right-sided Heart Failure

Left-sided Heart Failure: Systolic Failure, Diastolic Failure

Congestive Heart Failure

Request For Customization of This Exclusive Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/1910

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com